Neurocrine Biosciences appointed Samir Siddhanti chief business officer, adding him to the executive Management Committee.
He will lead enterprise growth strategy, covering business development, corporate strategy, alliance management, and program management.
Siddhanti joined Neurocrine in 2017 and was most recently vice president of business development, leading transactions including the $2.9 billion Soleno Therapeutics acquisition.
He previously worked in biotechnology equity research at Goldman Sachs.
NBIX•
